Trial Profile

A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Cirtuvivint (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary) ; Prednisone (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Biosplice Therapeutics

09 Aug 2024 Status changed from active, no longer recruiting to discontinued.
18 Oct 2022 Planned primary completion date changed from 1 Jul 2026 to 1 Jul 2024.
18 Oct 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com